Promethium Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Promethium Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37M	Sell	41,150 -3,500	-8%	-$201K	1.14%	27
2026 Q1	$2.71M	Buy	44,650 +600	+1%	+$35K	1.4%	23
2025 Q4	$2.38M	Hold	44,050	–	–	1.28%	24
2025 Q3	$1.99M	Hold	44,050	–	–	1.14%	33
2025 Q2	$2.04M	Sell	44,050 -2,000	-4%	-$98.2K	1.24%	30
2025 Q1	$2.81M	Sell	46,050 -10,000	-18%	-$583K	1.8%	17
2024 Q4	$3.17M	Sell	56,050 -13,500	-19%	-$754K	2.17%	8
2024 Q3	$3.6M	Buy	+69,550	New	+$3.26M	2.54%	4

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Promethium Advisors's BMY Position: Q2 2026 in Review

Promethium Advisors reduced its Bristol-Myers Squibb (BMY) stake by 7.8% in Q2 2026, selling an estimated $201K and leaving 41,150 shares worth $2.37M. The position accounts for 1.14% of the portfolio, ranked #27.

Promethium Advisors first reported a position in BMY in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.6M in Q3 2024. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Promethium Advisors held 41,150 shares of Bristol-Myers Squibb worth $2.37M as of Q2 2026.
Promethium Advisors sold 3,500 Bristol-Myers Squibb shares in Q2 2026, an estimated $201K.
Bristol-Myers Squibb made up 1.14% of Promethium Advisors's portfolio in Q2 2026, its #27 holding.
Promethium Advisors first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 8 quarters since.
Promethium Advisors's Bristol-Myers Squibb position peaked at $3.6M in Q3 2024.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Promethium Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.